九典制药(300705) - 2023 Q3 - 季度财报

Shareholder Information - The total number of common shareholders at the end of the reporting period was 10,585, an increase from the previous period[13]. Financial Performance - The company's operating revenue for the current period is CNY 675,217,656.27, representing an increase of 18.83% compared to the same period last year[29]. - The net profit attributable to shareholders for the current period is CNY 110,408,322.44, reflecting a growth of 43.06% year-over-year[29]. - The net profit for the current period was ¥309,990,436.06, representing a 48.7% increase from ¥208,389,289.18 in the previous period[42]. - Basic earnings per share increased to ¥0.90, compared to ¥0.63 in the prior period[42]. Cash Flow - The net cash flow from operating activities is CNY 387,195,113.24, which is a significant increase of 132.53% compared to the previous year[29]. - The net cash flow from financing activities surged by 820.31% to ¥328,229,201.50, primarily due to cash received from the issuance of convertible bonds[32]. - The net cash flow from financing activities was $328.23 million, a substantial increase from $35.67 million previously[44]. - The net increase in cash and cash equivalents was $434.09 million, contrasting with a decrease of $82.95 million in the previous period[44]. Assets and Liabilities - The company's cash and cash equivalents amounted to ¥784,164,729.18, up from ¥345,843,239.68 at the beginning of the year, representing a growth of approximately 127.5%[17]. - The total current assets reached ¥1,686,691,228.11, compared to ¥1,206,494,604.41 at the start of the year, indicating an increase of about 39.7%[17]. - The company's total equity attributable to shareholders was ¥1,906,922,503.10, an increase from ¥1,552,620,644.89, reflecting a growth of approximately 22.7%[20]. - Total assets at the end of the reporting period amount to CNY 2,999,127,081.78, marking a 30.42% increase from the end of the previous year[29]. - Total liabilities rose to ¥1,092,204,578.68, up from ¥747,050,467.29 in the previous period[39]. Inventory and Receivables - The company's inventory increased to ¥278,314,115.01 from ¥241,039,257.35, marking a rise of about 15.4%[17]. - The company reported a significant increase in accounts receivable, which rose to ¥479,178,966.62 from ¥458,194,943.04, indicating a growth of about 4.6%[17]. Research and Development - Research and development expenses rose by 118.71% to ¥18,829,141.97, reflecting increased spending on R&D projects[32]. - Research and development expenses rose to ¥157,352,877.64, up 22.4% from ¥128,529,979.49 in the previous period[41]. Government Subsidies and Other Income - The company has recognized government subsidies amounting to CNY 3,408,460.25 during the current period[29]. - Other income surged by 100.08% to ¥14,790,595.91, mainly due to increased government subsidies received[32]. Financial Stability - The company has maintained a stable financial position with total liabilities and equity amounting to ¥2,999,127,081.78, compared to ¥2,299,671,112.18 in the previous period, reflecting a growth of approximately 30.5%[20]. - The company has no non-recurring gains or losses that would affect the financial results, ensuring the accuracy of the reported figures[10]. Audit and Reporting - The company has not undergone an audit for the third quarter report[25].